New Dental Health Warning for Some Buprenorphine Products
January 12, 2022
Cibinqo Approved to Treat Atopic Dermatitis
January 14, 2022
January 13, 2022 – RyaltrisTM (olopatadine hydrochloride/mometasone furoate monohydrate) nasal spray has been FDA approved to treat the symptoms of seasonal allergic rhinitis in patients who are at least 12 years old.
- Ryaltris combines an antihistamine and a corticosteroid. Recommended dosing is two sprays in each nostril twice daily.
- Launch date and pricing plans are not yet available. Ryaltris is manufactured by Seqirus.